Atrial fibrillation (AF) is a worldwide epidemic associated with significant morbidity and mortality, often due to disabling or fatal thromboembolic stroke. Oral anticoagulation is highly effective at preventing ischaemic stroke and improving all-cause survival in patients with nonvalvular AF. Despite the efficacy of oral anticoagulation, many patients are not treated due to either absolute or perceived contraindications to therapy, including bleeding. Left atrial appendage (LAA) closure has emerged as a mechanical alternative to pharmacologic stroke prevention. Initial and mid-term clinical trial data suggest that LAA closure is safe, with less intracranial bleeding, and a net clinical benefit that appears to be non-inferior to oral anticoagulation. However, concern remains over the possible increased risk of ischaemic stroke in long-term follow-up. Careful patient selection for LAA closure is paramount. Patients with prior intracranial bleeding or recurrent serious bleeding who are not eligible for long-term oral anticoagulation are typical candidates for LAA closure; however, other populations may benefit as well, such as patients with end-stage renal disease. Clinical investigation and randomized trials are needed to clarify the best methods of LAA occlusion, optimal pharmacologic strategies in the short-term after LAA closure, and to identify patient populations who will derive the most benefit from LAA occlusion. In this article, we review the rationale for LAA closure, the currently available devices and their evidence base, patient selection, challenges in management, and future directions for LAA closure science.
Among patients who can tolerate warfarin or NOAC therapy, recurrent serious bleeding, and/or intracranial bleeding usually leads to cessation of therapy. Approximately, 1 in 5 patients discontinued NOAC therapy in randomized clinical trials. Thus, although effective therapies for stroke prevention exist, there is a clear need for other, better methods of stroke prevention.
Left atrial appendage (LAA) occlusion has emerged as a potential alternative for stroke prevention in patients who cannot tolerate oral anticoagulation. In the fibrillating atrium, stasis in the LAA can lead to thrombus formation. 9 The LAA is a remnant structure of the primordial left atrium and it is a crenellated blind pouch with one or more lobes. Autopsy and surgical data suggest that anywhere from 35 to 91% of atrial thrombi are found in the LAA. 10, 11 Transoesophageal echocardiography (TEE) suggests that the vast majority of AF-related stroke results from LAA thromboembolism. 12 These observations provide the rationale for LAA closure as a means of stroke prevention in patients with AF. While thromboembolism remains the predominant mechanism of stroke in patients with AF, it is not the only mechanism. Not all strokes in patients with AF are due to thromboembolism from the LAA. Atrial fibrillation itself is associated with a hypercoagulable state. 13, 14 Data from implanted devices have shown that among those with AF, 45% of strokes occur without any AF within 30 days of the stroke event. 15 While the aetiology of these strokes may not be completely independent from AF, patients with AF frequently have risk factors for vascular-non-cardioembolic stroke as well. Finally, there may also be a rationale for LAA occlusion in patients who continue to have a high risk of stroke despite oral anticoagulation. Combination therapy with LAA occlusion and oral anticoagulation might be an effective means of targeting residual risk in those with very high CHA 2 DS 2 -VASc scores who can tolerate oral anticoagulation.
Methods of left atrial appendage closure Surgical methods
There are several methods of LAA closure, including percutaneous and surgical approaches. Early experience with LAA elimination and/ or closure dates back to 1949 and was limited to surgical methods. 16 The left atrial appendage occlusion study (LAAOS) was the first randomized study of LAA closure. 17 The left atrial appendage occlusion study was a single-centre trial that randomized 77 CABG patients to LAA with staples or suture vs. control, but only 14% had AF. Successful LAA occlusion was only achieved in 66% of patients and two patients in the LAAO arm developed stroke or transient ischemic attack (TIA) during the initial hospitalization. There were no other cerebrovascular events after discharge. Therefore, over a total mean follow-up of 13 months, 2 of 52 patients in the LAAO group experienced a stroke. The follow-up left atrial appendage occlusion study II (LAAOS II) randomized 51 patients undergoing cardiac surgery with AF and increased risk of stroke to LAA occlusion vs. no occlusion. 18 Meta-analysis of two randomized trials and five observational studies of surgical LAA closure in the setting of cardiac surgery (n ¼ 3653 patients) suggests that LAA closure is associated with a lower incidence of stroke at 30-day follow-up (0.95 vs. 1.9%; OR 0.46; P ¼ 0.005) and last follow-up (1.4 vs. 4.1%; OR 0.48; P ¼ 0.01). 21 Based upon the totality of the published data, current European Society of Cardiology and American Heart Association/American College of Cardiology guidelines suggest that surgical excision of the LAA may be considered in patients undergoing cardiac surgery or thoracoscopic AF surgery. (Grade IIB, Level of Evidence B/C; Table 1 ).
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Percutaneous methods
There are four commercially available means of percutaneous LAA closure in Europe ( Figure 1 ). 26 As shown in Figure 2 , results suggested that the WATCHMAN was non-inferior to dose-adjusted warfarin.
Moreover, there was a reduction of haemorrhagic stroke with Left atrial appendage occlusion WATCHMAN compared with warfarin (0.1 vs. 1.6 events per 100 patient-years; probability of superiority 99.8%). However, primary safety events were increased in the WATCHMAN arm (rate ratio 1.69, 95% CrI 1.01 -3.19) where 5% of patients had a serious pericardial effusion. In terms of overall benefit, it is important to note that the combined endpoint of disabling stroke or death was reduced significantly in the WATCHMAN arm (RR, 0.41; 95% CI, 0.22 -0.82) in longer follow-up at 2.3 years. 27 Due to several safety concerns in the PROTECT AF study as well as concerns about the selection of the PROTECT AF patients (i.e. lower risk), the PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with Atrial Fibrillation Versus Long-Term Warfarin Therapy) study was conducted in 407 patients with the same 2:1 randomization to WATCHMAN or dose-adjusted warfarin. 28 The PREVAIL trial mandated that (a) patients had more than one risk factor for stroke (mean CHADS 2 score was 2.6) in order to enrol a higher risk population and (b) that 25% of the implanting physicians had to be new operators in order to test that the procedure could be performed safely in those without prior experience. The results from PREVAIL are shown in Figure 3 . Despite the inclusion of new operators, the primary safety endpoint was met in PREVAIL and only 2.2% of patients had early safety events, including pericardiocentesis in 1.5%. The first primary endpoint, the composite of stroke, systemic embolism, or unexplained death did not meet the pre-specified non-inferior margin of 1.75 (rate ratio 1.07, 95% CrI 0.57-1.89). However, the second co-primary endpoint of stroke or systemic embolism .7 days post-randomization was statistically non-inferior (stroke rate 0.0253 in the WATCHMAN arm vs. 0.0200 in the control arm). Patient-level meta-analysis utilizing the totality of the PROTECT, PREVAIL, and continued access registry data (2406 patients with 5931 patient-years of follow-up; mean follow-up 2.7 years) has demonstrated that WATCHMAN implantation in patients eligible for warfarin results in lower rates of haemorrhagic stroke (0.15 vs. 0.96 events/100 patient-years; HR 0.22, P ¼ 0.004), cardiovascular/unexplained death (1.1 vs. 2.3 events/100 patient-years; HR 0.48, P ¼ 0.006), and non-procedural-related bleeding (6.0 vs. 11.3 events/100 patient-years; HR 0.51, P ¼ 0.006). 29 On the other hand, compared with warfarin, WATCHMAN implantation (and chronic aspirin) is associated with higher rates of ischaemic stroke compared with dose-adjusted warfarin (1.6 vs. 0.9 events/100 patient-years; HR 
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AMPLATZER/AMULET
The ACP (Amulet; St Jude Medical, Plymouth, MA, USA) is an endocardial device designed to occlude the orifice and proximal segment of the LAA and is one of the most commonly used LAA occluders in Europe. The ACP is a self-expanding nitinol frame forming a lobe and a disc with polyester fabric and peripheral fixation hooks. The proximal disc is meant to enhance the potential for complete closure; the so-called pacifier principle. 31 The shape of the device and its flexibility allows it to conform to LAA chamber geometry and be implanted in relatively short appendages (ACP length , diameter). The ACP can accommodate LAAs between 12.6 and 28.5 mm in diameter. However, some advocate that the ACP can be placed in any size LAA, as it can be implanted deeper with the outside disc protecting the major part of the LAA. Long-term follow-up out to 4 years in 134 patients (mean CHA 2 DS 2 -VASc ¼ 4; mean HAS-BLED ¼ 4) treated with ACP implantation (96% success rate) has shown a post-implant risk of stroke of 0.8% per year and 2.5% per year for any thromboembolic event. 32 The largest published experience with the ACP is from a multicentre study (n ¼ 22 centres) of 1047 patients with a mean CHA 2 DS 2 -VASc ¼ 4 and 29% on oral anticoagulation. The procedural success rate was 97% with a periprocedural major adverse event rate of 5%. The annual stroke rate was 2.3% (31/1349 patient-years), which was 59% lower than expected based upon patient risk scores. 33 However, there are concerns over both acute and delayed (after discharge) device embolization, which occurred in as many as 5% of ACPtreated patients. 34, 35 It is important to note that cases of delayed embolization may represent unrecognized early dislodgments. A second-generation device, called the Amulet (with sizes up to 32 mm), is now available, and post-marketing surveillance studies are now enrolling. Early results in small cohorts suggest a lower rate of any peri-device leaks compared with the ACP device (48% with ACP vs. 8% with Amulet, P ¼ 0.01) and no significant risk of dislodgment. 36, 37 The AMPLATZER device is also undergoing evaluation in several randomized trials. The ELIGIBLE (efficacy of LAA closure after gastrointestinal bleeding) will randomize 120 patients to AMPLATZER implantation and 3 months of aspirin and clopidogrel vs. oral anticoagulation in patients with prior gastrointestinal bleeding (NCT01628068).
Wavecrest
The WaveCrest LAA occluder (Coherex Medical, Salt Lake City, UT, USA) has a nitinol frame with an ePTFE cover over a foam backing with exposed and flexible fixation anchors. The device is relatively short and is designed for more proximal deployment in the LAA. WAVECREST I enrolled 73 patients with a mean CHADS 2 score of 2.5, prior stroke in 34 and 49% with a contraindication to warfarin. Overall, LAA closure was achieved in 96% (n ¼ 70/73) with two patients developing tamponade during the implant procedure. 38 Several ongoing post-marketing observational studies are underway.
LARIAT endocardial/epicardial suture Distinct from the above described occluder-based methods, the Lariat LAA exclusion system is a combined endocardial and epicardial percutaneous method of LAA closure. The device uses a snare with a pre-tied suture that is delivered over the LAA using an epicardial approach. Snaring of the LAA is facilitated by a magnetic-tipped endovascular guidewire. The largest published multicentre series with the Lariat reports on a cohort of 154 patients with a mean CHADS 2 score of 2.8 and a mean HAS-BLED score of 3.2 (14% with prior intracranial haemorrhage). 39 Procedural success (complete LAA occlusion) was achieved in 86% (n ¼ 133/154). Inhospital major bleeding occurred in 9%, including seven cases of cardiac tamponade, three of which required surgical intervention due to cardiac perforation. Long-term follow-up data were limited, although there were two strokes, a case of bowel infarction, and one case of sudden death after hospital discharge. The reported frequency of LAA leaks with the Lariat has been variable, ranging between 2 and 24%, 40, 41 While the Lariat closure system has some advantages (ability to accommodate a large LAA orifice, the lack of need for post-procedure anticoagulation, etc.) and several cohort studies have shown acceptable procedural outcomes, there are some concerns over procedural safety. Systematic review has demonstrated a higher than anticipated need for urgent cardiac surgery (n ¼ 7 out of 309 procedures, 2.3%) due to LAA perforation and tamponade. 42 Patient selection for left atrial appendage closure
Given the durable reduction in stroke and improved survival with warfarin in patients with non-valvular AF and the significantly lower intracranial bleeding with NOACs compared with vitamin K antagonists, oral anticoagulation remains the first-line therapy for stroke prevention in AF. 23 Relative to warfarin, high-dose NOAC therapy is associated with a 19% lower risk of stroke or systemic embolism (RR 0.81, 95% CI 0.73 -0.91), a 51% reduction in haemorrhagic stroke (RR 0.49, 95% CI 0.38-0.64), and a 10% reduction in mortality (RR 0.90, 95% CI 0.85-0.95). 5 However, there is a paradox between the available randomized data and the greatest unmet clinical need for stroke prevention with LAA closure. In this paradox, the randomized clinical trials of LAA closure have enrolled patients who are eligible for oral anticoagulation, while the clinical need for LAA closure is greatest in those who cannot tolerate oral anticoagulation. Nonetheless, given the findings with LAA closure in randomized studies 26 -29 and the limited but supporting observational data in those with contraindications to oral anticoagulation, LAA closure seems to be a reasonable alternative in patients with contraindications to oral anticoagulation. Consistent with this, in the recent EWOLUTION registry of 1021 patients undergoing LAA closure with Watchman, 62% of patients were deemed unsuitable for long-term oral anticoagulation. 43 Some investigators and clinicians might argue that even patients with relative or minor contraindications to warfarin might benefit from LAA closure given the advantages in survival observed with WATCHMAN therapy at 4 years of follow-up; however, it is important to keep in mind that there are other alternatives in patients who are not suitable for warfarin. In particular, the AVERROES trial has shown that NOAC therapy with apixaban can be tolerated (and is superior to aspirin) in patients who have previously attempted and failed warfarin therapy. 44 Whether or not WATCHMAN and aspirin therapy is comparable or non-inferior to NOAC therapy remains unknown, but is an important area for future studies. At present, LAA occlusion should be reserved for patients who cannot tolerate oral anticoagulation as recommended in current guidelines.
23 Figure 4 illustrates an approach to stroke prevention in patients with non-valvular AF and risk factors for stroke. Inability to tolerate Left atrial appendage occlusion oral anticoagulation, prior serious bleeding in which the cause is not reversible (e.g. small bowel angiodysplasia), and intracranial bleeding are all situations in which, LAA closure is a reasonable treatment option. Some have hypothesized that patients at higher risk for bleeding, for example those with high HAS-BLED scores may also benefit from LAA closure. However, this is speculative and merits further study. It would seem plausible that the net clinical benefit of LAA closure might occur at a threshold bleeding risk/HAS-BLED score. It is important to keep in mind that prior investigations have shown that the net clinical benefit of oral anticoagulation is preserved across all bleeding scores. 45 Are there other special populations who might derive particular benefit from LAA closure? Patients with advanced chronic kidney disease and end-stage renal disease (ESRD) with AF have increased risk of thromboembolic events and bleeding events. 46, 47 In patients with ESRD, the aggregate evidence does not suggest clear benefit of oral anticoagulation. While patients with AF and ESRD have not been included LAA closure trials to date, LAA closure may be superior to oral anticoagulation for stroke prevention in these highrisk patients. Patients with bleeding diatheses who can tolerate antiplatelet agents but not oral anticoagulation are another population with increased risk of intracranial bleeding and represent another group in which LAA closure may be particularly attractive. As mentioned earlier, an additional patient population that could benefit from LAA closure is patients at very high risk of stroke. Many patients with multiple risk factors for stroke still have an unacceptably high risk of stroke despite oral anticoagulation. For example, in the ROCKET AF trial, patients with a CHA 2 DS 2 -VASc score of five or higher had a 2-year event rate in excess of five events per 100 patient-years despite anticoagulation. 47 Patients with high 'residual risk' despite optimal anticoagulation might potentially benefit from hybrid therapy in which indefinite oral anticoagulation is combined with LAA closure. For example, patients with very high CHA 2 DS 2 -VASc scores might benefit from LAA closure and long-term lowdose NOAC therapy. Although speculative, the treatment of residual risk in with hybrid therapy should be an area of future investigation and clinical trials.
Selecting a method for left atrial appendage closure
When selecting a method for LAA closure, there are several considerations that must be taken into account, including anatomic factors, prior surgical history, ability to tolerate anticoagulation, and need for other interventions. It is important to emphasize that there are no completed clinical trials comparing different devices or techniques for LAAO to guide an evidence-based selection. Patients with prior cardiothoracic surgery are not candidates for epicardial Lariat suture closure. Lariat closure may also be very difficult in patients with pectus excavatum, a superiorly directed LAA or an LAA that courses behind the pulmonary artery. 31 The width of the os, the length, and the shape of the LAA are also all very important to consider with endocardial approaches. A cardiac CT or cardiac MRI can be very helpful to better elucidate and clarify anatomy in conjunction with TEE images. If the LAA is wider than its length or if the length is less than 17 mm or greater than 30 mm, a WATCHMAN should be avoided. While there are observational data from the ASAP registry in patients who cannot tolerate oral anticoagulation, 30 the best available data derive from clinical trial data in which patients received 45 days of warfarin post-procedure. Other endocardial occluder devices also have restrictions based upon the width 35, 48 Challenges in left atrial appendage closure Left atrial appendage closure presents several challenges. One of the biggest challenges for patients who have a history of bleeding is that most LAAO interventions require long-term antiplatelet therapy. In randomized clinical trials, antiplatelet therapy seems to have similar bleeding risks compared with oral anticoagulation. For example, in the apixaban vs. acetylsalicylic acid to prevent stroke in AF patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial, major bleeding was not significantly different in those treated with apixaban vs. aspirin (1.4 vs. 1.2% per year; HR 1.13; 95% CI, 0.74-1.75; P ¼ 0.57). 49 Similarly, there was no difference in intracranial bleeding either (n ¼ 11 with apixaban vs. n ¼ 13 with aspirin). Thus patients who can tolerate LAAO are still exposed to significant chronic bleeding risk with antiplatelet therapy. Moreover, many patients with ongoing bleeding cannot even tolerate the intraprocedural anticoagulation required during occluder implant procedures. Finally, in patients with active or suspected LAA thrombus, LAAO is contraindicated. While relatively uncommon, inadequate seal and LAA leak do occur. Typically, Doppler flow jets ,5 mm are not considered clinically significant and many resolve on follow-up imaging. Depending upon the type of device, LAA leak can be from the edge of the device as in the case of the WATCHMAN or ACP or a central 'gunnysack' leak as observed with the Lariat suture exclusion. 50 Post hoc analysis of the PROTECT AF data suggests that the incidence of stroke in patients with minor or major leaks is small ( 1% per year) and did not appear elevated compared with patients without the evidence of peri-device flow. 51 In a multicentre observational study, 3 patients out of 259 had a stroke after Lariat LAA exclusion. These events did not appear related to device leak since all three patients had complete closure. 50 Secondary closure of leaks with the Amplatzer occluder device has been reported in both Lariatand WATCHMAN-treated patients. 52, 53 Increasing intravascular volume status with a fluid bolus prior to implant may enlarge LAA dimensions, may improve device fit, and may result in a lower risk of LAA leak. 54 Thrombus formation on LAA occlusion devices has been observed and remains a challenging clinical problem when it occurs. Pouches of communicable blood flow due to leaks or the surface of the device itself may serve as foci for thrombus formation. In the PROTECT AF trial, 4.2% of successfully implanted devices were observed to have thrombus on follow-up TEE imaging; however, the rate of stroke in these patients was very low at 0.3 events per 100 patient-years. 55 Despite the low event rate observed in patients with thrombus, continued oral anticoagulation is advisable, particularly in cases of mobile thrombus. Anticoagulation should be continued until resolution of thrombus is demonstrated with TEE. 31 While the primary intention of LAA closure therapy is to prevent stroke without the need for oral anticoagulation, the optimal medical therapy in patients who are .6 months post closure has not been defined. Most advocate aspirin monotherapy, however, it remains possible that other antiplatelet therapies may offer improved stroke prevention, particularly for non-LAA mechanisms of stroke (i.e. small vessel disease). This question is particularly relevant and challenging in patients with concomitant vascular disease.
Future directions
Important areas for future investigation include the elucidation of long-term outcomes in patients treated with LAA closure, comparative data between devices, the identification of special patient populations who will derive net clinical benefit from LAA closure, and defining optimal medical therapy after LAA closure. Additionally, the management of subsequent cardiovascular procedures in patients who have undergone LAA closure is also an important area where more data are needed. The optimal management of cardioversion or ablation in patients with LAA closure remains undefined. A list of top priorities for future research are highlighted in Table 2 . 
Conclusion
Left atrial appendage closure is a viable therapeutic alternative in select patients with non-valvular AF and a compelling reason to avoid long-term oral anticoagulation. At present, the WATCHMAN device has the largest evidence base and the only device supported by randomized trials. However, device selection should be tailored to the individual patient. Patient selection remains the most important step in LAA closure therapy. As clinical investigation continues, physicians will have more data to help determine who will derive the most benefit from LAA closure compared with medical therapy. However, for now, LAA closure may be considered in patients with a high risk of stroke and contraindications to long-term oral anticoagulation.
